Journal Watch · Annals of the Rheumatic Diseases · 2026

Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.

These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.

Sattar N, Scilletta S, Stefanski A et al.Annals of the Rheumatic Diseases3 min readPharma relevance 85/100

DOI: 10.1016/j.ard.2025.10.009PMID: 41198460Study type: randomised / controlled clinical trial

TL;DR

These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.

Key findings

  • Mediation analysis suggested that weight reduction explained 72.7% of SUA reduction.<h4>Conclusions</h4>In this post hoc analysis, in participants with obesity or overweight, tirzepatide was associated with meaningfully reduced SUA levels, regardless of participants' baseline BMI or SUA levels, and appeared to be so primarily via weight reduction.
  • These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.

Numbers at a glance (from the abstract)

20.9%72.7%or 15P < .001P = .610P = .362

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The association between weight changes and SUA changes was evaluated by mediation analysis.<h4>Results</h4>Treatment with all dose groups of tirzepatide was associated with significant reductions in SUA, compared to placebo. At week 72, the mean change in SUA was -0.69 mg/dL (SE: 0.04), -0.92 mg/dL (0.04), and -0.95 mg/dL (0.04) with 5, 10, and 15 mg of tirzepatide (all P < .001), respectively, and -0.18 mg/dL (0.04) with placebo. SUA levels reduced significantly over time compared to placebo, regardless of baseline uric acid quartiles (P = .610) and baseline BMI values (P = .362).

Full abstract (original)

Background: <h4>Objectives</h4>This study aimed to test whether tirzepatide, a dual GLP-1RA/GIP agonist, approved for weight management, would be associated with lowered serum uric acid (SUA) levels via its weight reduction properties.<h4>Methods</h4>A post hoc analysis of the SURMOUNT-1 trial, a randomised placebo-controlled trial involving 2539 adults with obesity or overweight (body mass index [BMI] ≥ 30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> and at least 1 weight-related complication), randomised to tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks. Tirzepatide treatment over 72 weeks decreased weight by up to 20.9%. SUA was measured at baseline and multiple time points during the 72-week study across the 3 active trial arms, and changes were compared to the placebo arm.

What they did: The association between weight changes and SUA changes was evaluated by mediation analysis.<h4>Results</h4>Treatment with all dose groups of tirzepatide was associated with significant reductions in SUA, compared to placebo. At week 72, the mean change in SUA was -0.69 mg/dL (SE: 0.04), -0.92 mg/dL (0.04), and -0.95 mg/dL (0.04) with 5, 10, and 15 mg of tirzepatide (all P < .001), respectively, and -0.18 mg/dL (0.04) with placebo. SUA levels reduced significantly over time compared to placebo, regardless of baseline uric acid quartiles (P = .610) and baseline BMI values (P = .362).

Results & conclusions: Mediation analysis suggested that weight reduction explained 72.7% of SUA reduction.<h4>Conclusions</h4>In this post hoc analysis, in participants with obesity or overweight, tirzepatide was associated with meaningfully reduced SUA levels, regardless of participants' baseline BMI or SUA levels, and appeared to be so primarily via weight reduction. These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.

Abstract © the authors / Annals of the Rheumatic Diseases (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.ard.2025.10.009 · PubMed 41198460.

Why it matters for pharma & biotech

  • Directly relevant to teams in metabolic / GLP-1 therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: metabolic / GLP-1 therapeutics · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Annals of the Rheumatic Diseases study find?

These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.

What type of study is this?

It is a randomised / controlled clinical trial, published in Annals of the Rheumatic Diseases in 2026. The association between weight changes and SUA changes was evaluated by mediation analysis.<h4>Results</h4>Treatment with all dose groups of tirzepatide was associated with significant reductions in SUA, compared to placebo.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.ard.2025.10.009. PubMed ID: 41198460. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Sattar N, Scilletta S, Stefanski A et al.. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.. Annals of the Rheumatic Diseases (2026). DOI: 10.1016/j.ard.2025.10.009.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/tirzepatide-and-change-in-uric-acid-and-its-association-with-weight-redu-510009/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides